Aurobindo Pharma Latest News

  1. The USFDA had conducted an inspection from April 10, 2017 to April 18, 2017
    Date:19-04-2017
  2. Pursuant to Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Aurobindo Pharma has informed about the Compliance Certificate for the half year ended 31.03.2017.

    Th...

    Date:10-04-2017
  3. Pursuant to Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Aurobindo Pharma has informed about Investor Grievance Report for the Quarter ended 31.03.2017.

    The ...

    Date:10-04-2017
  4. The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Auryn Labs.

    The above information is a part of company’s filings submitted to...

    Date:05-04-2017
  5. The company’s Abacavir Sulfate and Lamivudine tablets are the AB rated generic equivalent of VIIV Healthcare Company's Epzicom tablets
    Date:30-03-2017
  6. Aurobindo Pharma has informed about press release titled ‘Aurobindo Pharma receives USFDA Approval for Generic Epzicom tablets’.

    The above information is a part of company’s filings submi...

    Date:30-03-2017
  7. Aurobindo's Abacavir Sulfate and Lamivudine tablets are the AB rated generic equivalent of VIIV Healthcare Company's Epzicom tablets
    Date:30-03-2017
  8. The company’s Meropenem injection is a generic equivalent of AstraZeneca Pharmaceuticals’ Merrem Injection
    Date:28-03-2017
  9. The company’s Meropenem injection is a generic equivalent of AstraZeneca Pharmaceuticals’ Merrem Injection
    Date:28-03-2017
  10. The approved product has an estimated market size of $235 million for the twelve months ending December 2016
    Date:21-03-2017
Return to Top
Connect with us Facebook
Connect with us Facebook
Connect with us Linkedin
Connect with us Pintrest
Connect with us Google Plus
Connect with us You Tube
Connect with us Mobile App
Request a Call Back
We will guide you on how to find
the Right stocks at the Right prices.
Mobile
Invalid Mobile Number
x
Thank you for
contacting us.
We will call you
shortly.